OncoMatch/Clinical Trials/NCT07702838
Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
Is NCT07702838 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for uterine cervical neoplasms.
This study explores the therapeutic effect of carbon ion radiotherapy plus immunotherapy and chemotherapy for locally advanced cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIB, IIIA, IIIB, IIIC1, IIIC2, IVA (other)
Stage IIB-IVA disease per the 2018 FIGO staging system
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4)
Prior receipt of immunotherapy agents (including anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.)
Cannot have received: systemic therapy for cervical cancer
Exception: Conisation of the cervix is permitted
Prior radical surgery, radiotherapy, or systemic therapy (including investigational agents) for cervical cancer. Note: Conisation of the cervix is permitted.
Lab requirements
Blood counts
ANC ≥ 1500/μL; Platelet count ≥ 100,000/μL; Haemoglobin ≥ 9.0 g/dL (or ≥ 5.6 mmol/L)
Kidney function
Creatinine clearance ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN; if total bilirubin > 1.5 × ULN, direct bilirubin ≤ ULN; AST and ALT ≤ 2.5 × ULN
Adequate function of major vital organs (bone marrow, liver, kidney, etc.), with laboratory values meeting the following criteria within 1 week prior to treatment: Absolute neutrophil count (ANC) ≥ 1500/μL; Platelet count ≥ 100,000/μL; Haemoglobin ≥ 9.0 g/dL (or ≥ 5.6 mmol/L); Creatinine clearance ≥ 50 mL/min; Total bilirubin ≤ 1.5 × upper limit of normal (ULN); if total bilirubin > 1.5 × ULN, direct bilirubin shall be ≤ ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; International Normalised Ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (excluding patients receiving anticoagulant therapy within the therapeutic range).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07702838 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or IIIA or IIIB or IIIC1 or IIIC2 or IVA is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages